Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects / Gavazzoni, M; Lombardi, C; Vizzardi, E; Gorga, E; Sciatti, E; Rossi, Laura; Belotti, A; Rossi, G; Metra, M; Raddino, R. - In: EUROPEAN JOURNAL OF PHARMACOLOGY. - ISSN 0014-2999. - (2018).
Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects
Metra M;
2018-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
